Open AccessAssociation of APOE polymorphisms with lipid-lowering efficacy of statins in atherosclerotic cardiovascular diseases
Author(s) -
Yuexi Wang,
Xiaohong Du,
Ruifeng Zhao,
Juan Niu,
Haixu Wang,
Jing Li
Publication year - 2021
Publication title -
annals, academy of medicine, singapore/annals of the academy of medicine, singapore
Language(s) - English
Resource type - Journals
ISSN - 0304-4602
DOI - 10.47102/annals-acadmedsg.2020505
Subject(s) - atorvastatin , apolipoprotein e , medicine , genotype , apolipoprotein b , statin , cholesterol , lipoprotein , lipid profile , blood lipids , endocrinology , disease , gene , genetics , biology
Apolipoprotein E (APOE) gene is a promising candidate for the diagnosis ofhyperlipoproteinaemia and atherosclerosis. Polymorphisms in APOE have been reported to result indifferential efficacies of statins in atherosclerotic cardiovascular diseases.Method: We classified APOE genotypes of 225 patients treated with atorvastatin and analysed therelationship between genotypes and blood lipid levels.Results: The baseline levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C)were significantly lower in APOE ε4 than APOE ε3 carriers. Levels of TC and LDL-C decreasedsignificantly after 1 month of atorvastatin treatment. Statins have a higher significant effect in reducingTC and LDL-C levels in APOE ε4 genotype.Conclusion: Polymorphism in APOE is related to the efficacy of atorvastatin in reducing the levelsof TC and LDL-C.Keywords: Apolipoprotein E, lipid-lowering efficacy, polymorphism, statin, total cholesterol